Axios @axios
Treatments to reduce maternal mortality or pre-term births — issues that disproportionately impact women of color — are few and far between. Now there's one fewer option after an FDA panel recommended to pull Makena from the market. https://t.co/WiKTepPbI1 — PolitiTweet.org